Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Dose Escalation Followed by Dose Expansion, Safety and Tolerability Trial of CAN04, a Fully Humanized Monoclonal Antibody Against IL1RAP, in Subjects With Solid Malignant Tumors

NCT03267316 is registered in ClinicalTrials.gov with Cantargia AB as lead sponsor.

NCT NCT03267316
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03267316 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Dose Escalation Followed by Dose Expansion, Safety and Tolerability Trial of CAN04, a Fully Humanized Monoclonal Antibody Against IL1RAP, in Subjects With Solid Malignant Tumors
Lead sponsor
Cantargia AB
Phase
Phase 1/2
Overall status
Completed
Start date
September 19, 2017
Completion date
March 14, 2024
Enrollment
167 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, non small cell lung cancer, pancreatic ductal adenocarcinoma, triple negative breast cancer